Krystal Biotech, Inc. $KRYS Holdings Lowered by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP decreased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 4.9% in the first quarter, HoldingsChannel reports. The firm owned 468,990 shares of the company’s stock after selling 23,978 shares during the period. Dimensional Fund Advisors LP’s holdings in Krystal Biotech were worth $121,130,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the stock. Sound Income Strategies LLC raised its holdings in Krystal Biotech by 1,270.0% during the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock worth $34,000 after buying an additional 127 shares during the period. Greenline Wealth Management LLC acquired a new stake in shares of Krystal Biotech during the fourth quarter valued at approximately $34,000. Danske Bank A S acquired a new stake in shares of Krystal Biotech during the third quarter valued at approximately $35,000. UMB Bank n.a. lifted its position in shares of Krystal Biotech by 34.6% in the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after acquiring an additional 37 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its position in shares of Krystal Biotech by 788.9% in the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after acquiring an additional 142 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $347.27, for a total transaction of $347,270.00. Following the transaction, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. This represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock worth $8,243,923 over the last three months. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Up 5.0%

NASDAQ KRYS opened at $351.82 on Tuesday. The stock has a market capitalization of $10.37 billion, a PE ratio of 47.03 and a beta of 0.50. The company has a 50 day moving average price of $334.97 and a two-hundred day moving average price of $293.58. Krystal Biotech, Inc. has a 12-month low of $130.50 and a 12-month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The company had revenue of $116.36 million for the quarter, compared to analyst estimates of $112.11 million. As a group, equities analysts anticipate that Krystal Biotech, Inc. will post 7.31 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on KRYS. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research note on Monday, July 13th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a report on Tuesday, May 5th. HC Wainwright increased their target price on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Bank of America lifted their price target on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $360.67.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.